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Abstract
Background: Tolvaptan is a selective vasopressin receptor antagonist. Nitric Oxide (NO) promotes renal water and
sodium excretion, but the effect is unknown in the nephron’s principal cells. In a dose-response study, we measured
the effect of tolvaptan on renal handling of water and sodium and systemic hemodynamics, during baseline and NO-
inhibition with L-NMMA (L-NG-monomethyl-arginine).
Methods: In a randomized, placebo-controlled, double blind, cross over study, 15 healthy subjects received tolvaptan
15, 30 and 45 mg or placebo. L-NMMA was given as a bolus followed by continuous infusion during 60 min. We
measured urine output (UO), free water clearance (CH2O), fractional excretion of sodium (FENa), urinary aquaporin-2
channels (u-AQP2) and epithelial sodium channels (u-ENaCγ), plasma vasopressin (p-AVP) and central blood pressure (cBP).
Results: During baseline, FENa was unchanged. Tolvaptan decreased u-ENaCγ dose-dependently and increased p-AVP
threefold, whereas u-AQP2 was unchanged. During tolvaptan with NO-inhibition, UO and CH2O decreased
dose-dependently. FENa decreased dose-independently and u-ENaCγ remained unchanged. Central BP increased
equally after all treatments.
Conclusions: During baseline, fractional excretion of sodium was unchanged. During tolvaptan with NO-inhibition,
renal water excretion was reduced dose dependently, and renal sodium excretion was reduced unrelated to the dose,
partly via an AVP dependent mechanism. Thus, tolvaptan antagonized the reduction in renal water and sodium
excretion during NO-inhibition. Most likely, the lack of decrease in AQP2 excretion by tolvaptan could be attributed to
a counteracting effect of the high level of p-AVP.
Trial registration: Clinical Trial no: NCT02078973. Registered 1 March 2014.
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Background
Water and salt balance in the body is a result of complex
interactions of hormones, especially vasopressin and the
components in the renin-angiotensin-aldosterone sys-
tem. Vasopressin sensitive aquaporin2 water channels
and epithelial sodium channels are expressed in the
principal cells in the collecting ducts [1–3]. Stimulation
of vasopressin receptors (V2) facilitates renal absorption
of water and sodium [4–7]. This mechanism is antago-
nized by tolvaptan, a selective V2 receptor antagonist.
NO may affect the renal urine concentration mechanism
by membrane insertion of AQP2 in the collecting ducts
principal cells [8–11]. However, it is debated whether
NO inhibits or stimulates AQP-mediated water trans-
port. In a previous study, we showed that NO promotes
water excretion by a partly AVP dependent mechanism
[12]. NO is synthesized from L-arginine by NO-synthase,
an enzyme that is competitively inhibited by L-NMMA [13].
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Systemic NO inhibition causes reduction in diuresis, natri-
uresis, and increases in blood pressure [14–16]. Several
studies have documented the effect of selective V2 receptor
antagonism on renal sodium and water excretion, but
whether NO is involved in the response of the V2 receptors
in the renal tubular and vascular function is not clarified.
Recently, tolvaptan has been approved by the EMA for
treatment of autosomal dominant polycystic kidney disease
[17–21]. Also, tolvaptan is effective in conditions of dilu-
tional hyponatremia, associated with congestive heart fail-
ure, cirrhosis and the syndrome of inappropriate secretion
of antidiuretic hormone (SIADH) [22–26]. However, The
European guideline on hyponatremia recommends against
the use of tolvaptan in the clinical management of SIADH
[27]. Thus, based on a most likely wide spread use of tolvap-
tan in the future, an in-depth knowledge is necessary re-
garding the effect of the tolvaptan on renal tubular function,
vasoactive hormones and blood pressure. Our laboratory
has previously investigated the effect of tolvaptan 15 mg at
baseline and during tolvaptan with NO-inhibition in a ran-
domized, placebo-controlled, double-blinded, crossover
study [12]. We demonstrated a clear effect of tolvaptan
15 mg at baseline and during tolvaptan with NO-inhibition
on renal water excretion and the activity in ENaC, but no
knowledge is available about the effect of different doses re-
garding interaction between tolvaptan and NO-inhibition.
In the present study, we hypothesized 1. that tolvaptan
increases water and sodium excretion in a dose-dependent
manner, 2. that systemic NO-inhibition reduces this re-
sponse dose-dependently, and 3. An increase in blood pres-
sure and vasoactive hormones at baseline and during
NO-inhibition counteracts tolvaptan’s effect on the tubular
sodium and water transport at least partially.
The purpose was to measure the effect tolvaptan on 1.
glomerular filtration rate and renal absorption of water and
sodium (GFR (51Cr-EDTA-clearance), urinary output (UO),
free water clearance (CH2O), fractional excretion of sodium
(FENa), urinary excretion of aquaporin 2 (u-AQP2), and
urinary excretion of a protein fragment of the epithelial so-
dium channel (u-ENaCγ), 2.blood pressure (brachial blood
pressure (Bbp), central BP (cBP), pulse wave velocity (PW),
augmentation index (AI)), and 3. vasoactive hormones in
plasma(vasopressin (p-AVP), angiotensinII (p-AngII), renin
(PRC), and aldosterone (p-Aldo)), both at baseline and dur-
ing tolvaptan with NO-inhibition in a randomized, placebo-





Healthy non-smoking men and women, age between 18
and 40 year. and with BMI between 18.5 and 30 kg/m2
were enrolled.
Exclusion criteria
Exclusion criteria were; arterial hypertension (bBP >
140 mmHg systolic and/or >90 mmHg diastolic), history
or clinical signs of neoplastic disease or disease of the
heart, lungs, kidneys or endocrine organs, drug or alco-
hol abuse (I.e. > 14 units a week for women and 21 for
men), medical treatment except oral contraceptives,
pregnancy or breast-feeding, significant laboratory ab-
normalities in the screening test of blood samples (I.e.
abnormal hemoglobin, white cell count, plasma sodium,
plasma potassium, plasma creatinine, plasma alanine
aminotransferase or serum cholesterol, plasma bilirubin
and plasma albumin, and urine samples (I.e. albuminuria
or glucosuria), abnormal electrocardiogram, blood dona-
tion less than 1 month prior to the study.
In fertile women contraceptive treatment must be
used during and after the study period (I.e. oral con-
traceptives, spiral, depot injection of gestagen, sub
dermal implantation, transdermal contraceptive patch
and hormonal contraceptive vaginal ring).
Withdrawal criteria were development of one or more
of the exclusion criteria, brachial blood pressure increase
above 180/105 mmHg during infusion of L-NMMA,
withdrawal of consent or lack of compliance.
Study design
The trial was performed as a randomized, double-
blinded, placebo- controlled, crossover, dose-response
study in healthy subjects. The study consisted of four
treatment periods, placebo or tolvaptan 15, 30 and
45 mg, with an intermediate wash- out period of at least
3 weeks to eliminate any carryover effects.
Medications
Tolvaptan (SAMSCA®, Otsuka, Tokyo, Japan) 15, 30 and
45 mg or placebo were coated in identical gelatine cap-
sules and were orally administered at 8:00 AM.
L-NMMA (Bachem, Weil am Rhein, Germany) was
dissolved in isotonic saline solution and given intraven-
ously at 11:00 AM.
Number of subjects
Free water clearance (CH2O) was used as the main effect
variable. With a minimal relevant difference of 6 ml/min
with an estimated standard deviation (SD) of 4 ml/min,
12 subjects were needed using a level of significance of
5% and a statistical power of 90%. Due to possible drop
outs 15 subjects were included.
Recruitment
Healthy volunteers were recruited by advertising in pub-
lic institutions and private companies.
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Effect variables
CH2O was the primary effect variable. The secondary ef-
fect variables were 1) renal function (51Cr-EDTA-clear-
ance, UO, u-AQP2, u-ENaCγ, FENa), 2) hemodynamics
(bBP, cBP, PWV, AI and 3) vasoactive hormones (PRC,
p-ANG II, p-Aldo, p- AVP).
Diet
Four days prior to each treatment period subjects con-
sumed a standardized diet of 11.000 KJ day−1. The diet
was delivered from our facilities and was composed of
15% proteins, 55% carbohydrates and 30% fat following
general dietary guidelines. The sodium content was
150 mmol day−1. No additional sodium or other spices
was allowed. The daily fluid intake was 2.5 L including a
maximum of two cups of coffee or tea. No alcohol or
soft drink was allowed during the 4-day diet.
Experimental procedure
A 24-h urine was collected and a fasting period of 8 h
was performed prior to each examination day. The four
examinations were conducted at our facility from
7:45 AM to 1:00 PM. The procedures were identical on
all examination days.
At 8:00 AM subjects were given placebo or tolvaptan
15, 30 and 45 mg. An intravenous catheter was placed in
each arm to collect blood samples and infuse 51Cr-
EDTA.
At 8:00 AM and every 30 min, an oral water load of
175 ml was given.
BP was measured every 30 min from 8:30 AM to
1:00 PM. Based on results from a dose-finding study
made by our laboratory in healthy subjects [15], a bolus
of L-NMMA 4.5 mg/kg was given at 11:00 AM, followed
by continuous infusion (3 mg/kg/h) during 60 min. Dur-
ing infusion of L-NMMA BP was measured every 5 min,
and every 15 min after infusion of L-NMMA.
Blood samples were drawn every 30 min from 8:30 to
1:00 PM and were analyzed for p-Na, p-osm, p-
creatinine, p-albumin and p-51Cr-EDTA. Every 60 min;
at 11:00 AM (baseline), at 12:00 AM (after end of
L-NMMA infusion), and at 1:00 PM (60 min after end
of L-NMMA infusion), blood samples were drawn to
measure PRC, p-Aldo, p-Ang II and p-AVP.
Every 30 min from 9:30 AM to 1:00 PM, urine samples
were collected by voiding in standing or sitting position
after collecting BP measurements and blood samples.
Otherwise subjects were kept in a supine position in a
temperature-controlled (22–25 °C) and quiet room.
Baseline period was mean of the first three clearance pe-
riods. The urine samples were analyzed for osmolality,
creatinine, sodium, AQP2, ENaCγ and
51Cr-EDTA.
Applanation tonometry with SpygmoCor was per-




51Cr-EDTA-clearance was measured using the constant
infusion clearance technique with 51Cr-EDTA as refer-
ence substance.
CH2O was determined using the formula CH2O = UO-
Cosm, where Cosm is the osmolar clearance.
Clearance (C) of substance X was calculated as CX =
UX/(PX x UO), where UX denotes concentration of x in
urine, PX denotes concentration of x in plasma, and UO
is urine excretion rate.
Fractional excretion of sodium was determined ac-
cording to the following formula FENa = CNa/
51Cr-
EDTA-clearance x100%, where CNa is sodium clearance.
Urinary excretion of AQP2 and ENaCγ
Urine samples were kept frozen at −20 °C until assayed.
U-AQP2 and u-ENaCγ were measured by radioimmuno-
assay as previously described [28–30]. Antibodies were
raised in rabbits to synthetic peptide as previously de-
scribed [12]. U-ENaCγ was measured by radioimmuno-
assay as previously described [29]. Antibodies were
raised against the synthetic ENaCγ peptide in rabbits
and affinity purified as described previously [12, 31]. The
anti-AQP2 antibody was a gift from Soerens Nielsen,
The Water and Salt Research Center, Institute of Anat-
omy, Aarhus University, Denmark.
Vasoactive hormones in plasma
Blood samples collected for measurements of vasoactive
hormones were centrifuged and plasma was separated,
and kept frozen until assayed as previously described
[12]. PRC was determined by immunoradiometric assay
as previously described [12]. Aldo was determined by
RIA as previously described [12]. Ang II and AVP were
extracted from plasma and then determined by radio-
immunoassay [12, 32, 33].
Brachial and central blood pressure
Brachial BP was measured using an oscillometer (Omron
705IT) and recorded as previously described [12].
Central BP, PWA and carotid-femoral PWV were mea-
sured using applanation tonometry (SphygmoCor® CPV
system®, AtCor Medical, Sydney, Australia) as previously
described [12].
Routine analyses
Sodium, glucose, albumin, and hemoglobin were mea-
sured by routine methods in Department of Clinical
Biochemistry, Holstebro Hospital.
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Statistics
We performed statistical analyses by using IBM SPSS
statistics version 20.0.0 (SPSS Inc., Chicago, IL, USA).
General Linear Model Repeated Measures was used for
comparison between and within subjects to test differ-
ences between placebo and tolvaptan treatment at base-
line, during and after infusion of L-NMMA. One-way
ANOVA was performed for comparison between treat-
ment groups.
To compare differences between treatment groups at
baseline, paired sample t-test was performed during and
after infusion of L-NMMA. Statistical significance was at
<0.05 in all analyses. Data with normal distribution are
reported as means ± SD or SEM. Non-parametric test
was performed for data with non-normal distribution,




Twenty-seven healthy subjects were allocated to the
trial. Twelve of the participants were excluded; three due
to difficulties to gain intravenous access, two due to ar-
terial hypertension and seven due to withdrawal of con-
sent. Fifteen participants completed the study, three
males and 12 females. Median age was 24 ± 2 years,
weight 71.8 ± 13.1 kg, BMI 24 ± 4 kgm2. P-sodium 141 ±
1.7 mmol/L, p-potassium 3.7 ± 0.2 mmol/L, p-creatinine
68.7 ± 9.8 μmol/L. Systolic brachial blood pressure (SBP)
119 ± 10 mmHg, diastolic brachial blood pressure (DBP)
72 ± 8 mmHg.
Urine collection before the examination day
Twenty-four hours urine samples were collected prior to
every examination day. Values are shown in Additional
file 1: Table S1. No differences were measured in UO,
CH2O, u-AQP2, u-Na and u-K between the treatment
periods.
51Cr-EDTA-clearance
During tolvaptan with NO inhibition, 51Cr-EDTA-clear-
ance did not change significantly. The relative changes
in 51Cr-EDTA-clearance were non-significant in the four
treatment arms (Table 1).
Urinary output and free water clearance
Absolute and relative values of UO and CH2O are shown
in Fig. 1b-c and Table 1.
During L-NMMA infusion 90–120 min, UO decreased
significantly during all treatments (placebo: 3.0 ml/min
(49%); tolvaptan 15 mg: 4.8 ml/min (46%); tolvaptan
30 mg: 4.6 ml/min (40%); tolvaptan 45 mg: 3.6 ml/min
(31%)). As during baseline, the absolute level of UO
remained lower during placebo than tolvaptan, and no
significant differences were measured between the differ-
ent doses of tolvaptan. The relative changes from base-
line to L-NMMA infusion were the same during both
placebo and tolvaptan treatment. However, a tendency
to a dose response effect was seen both in the absolute
and relative measurements. During the post infusion
period 180–210 min, UO increased during placebo to
the same level as during baseline, but remained reduced
to the same levels during the three doses of tolvaptan
(placebo: 0.7 ml/min (6%); tolvaptan 15 mg: 4.1 ml/min
(40%); tolvaptan 30 mg: 4.6 ml/min (39%); tolvaptan
45 mg: 3.1 ml/min (31%)).
During L-NMMA infusion 90–120 min, CH2O de-
creased during all treatments (placebo: 2.1 ml/min
(57%); tolvaptan 15 mg: 4.3 ml/min (53%); tolvaptan
30 mg: 4.2 ml/min (38%); tolvaptan 45 mg: 3.3 ml/min
(35%)). The absolute level of CH2O remained lower dur-
ing placebo than tolvaptan treatment, and CH2O de-
creased significantly more after tolvaptan 15 mg
compared to 30 and 45 mg (p = 0.034 and 0.004 respect-
ively). The relative changes from baseline to L-NMMA
infusion did not deviate significantly between the four
treatments, but a tendency to a dose response effect was
measured with the lowest decrease in the highest tol-
vaptan dosis. During the post infusion period 180–
210 min, CH2O increased during placebo to the same
level as during baseline, but remained reduced during
tolvaptan treatment (placebo: 0.5 ml/min (0.5%); tol-
vaptan 15 mg: 4.2 ml/min (51%)); tolvaptan 30 mg:
4.2 ml/min (42%); tolvaptan 45 mg: 3.2 ml/min
(31%)). The difference in CH2O between the three tol-
vaptan doses was non-significant but a tendency to a
dose response effect was seen.
Fractional excretion of sodium
Absolute and relative values of FENa are shown in Fig. 2e
and Table 1.
During L-NMMA infusion 90–120 min, FENa de-
creased significantly after placebo and tolvaptan
15 mg (placebo: 0.37% (the relative decrease in per-
cent: 25%); tolvaptan 15 mg: 0.20% (14%); tolvaptan
30 mg: 0.12% (15%); tolvaptan 45 mg: 0.14% (12%)).
However, FENa decreased to the same level as after
tolvaptan 30 and 45 mg during the first 30 min of L-
NMMA infusion period 90–120 min. However, during
the last LNMMA infusion period 120–150 min, FENa
decreased to a significantly lesser extent after all tol-
vaptan doses compared with placebo (Table 1). Dur-
ing the post infusion period 180–210 min, FENa
increased after all treatments, but to a much higher
level after tolvaptan (placebo: 0.04% (the increase in
percent; 4%); tolvaptan 15 mg: 0.36% (46%); tolvaptan
30 mg:0.52% (44%); tolvaptan 45 mg: 0.42% (45%)).
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Table 1 Effect of tolvaptan 15, 30 and 45 mg at baseline, during and after NO-inhibition on the relative changes in GFR (Δ51 CrEDTA-
clearance), urinary output (Δ UO), free water clearance (Δ CH2O), urinary aquaporin 2 excretion rate (Δ AQP2), fractional excretion of
sodium (Δ FENa) and urinary ENaCγ excretion rate (Δ ENaCγ) in a randomized, placebo-controlled, double-blind, crossover, dose–response
study of 15 healthy subjects
Periods Baseline L-NMMA Post infusion p
(GLM-
within)
0–90 min 90–120 min 120–150 min 150–180 min 180–210 min
Δ 51Cr-EDTA-clearance (%)
Placebo - −5 ± 9 −1 ± 2 −5 ± 3 −3 ± 8 0.746
Tolvaptan 15 mg - −1 ± 7 2 ± 4 −2 ± 5 1 ± 5
Tolvaptan 30 mg - −5 ± 7 −3 ± 7 −3 ± 6 −4 ± 7
Tolvaptan 45 mg - 1 ± 6 1 ± 7 −0.1 ± 7 −2 ± 7
p (GLM between) 0.447
Δ UO (%)
Placebo - −49 (−59;−13) −41 (−49;−5) −26 (−42;5) −6 (−27;30) <0.0001
Tolvaptan 15 mg - −46 (−57;−34) −48 (−51;−38) −45 (−49;−39) −40 (−47;−26)
Tolvaptan 30 mg - −40 (−54;−32) −42 (−55;−34) −47 (−55;−28) −39 (−44;−25)
Tolvaptan 45 mg - −31 (−38;−27) −42 (−43;−31) −32 (−41;−26) −31 (−36;−24)
p (GLM between) 0.002
p (ANOVA) - 0.217 0.078 0.001 <0.0001
Δ CH2O (%)
Placebo - −57 (−78;−25) −47 (−63;0) −31 (−50;14) −0.5 (−31;37) <0.0001
Tolvaptan 15 mg - −53 (−66;−41) −56 (−60;−39) −54 (−66;−47) −51 (−59;−46)
Tolvaptan 30 mg - −38 (−65;−33) −46 (−66;−38) −51 (−63;−35 −42 (−61;−31)
Tolvaptan 45 mg - −35 (−49;−30) −47 (−57;−36) −33 (−54;−30) −31 (−46;−26)
p (GLM between) 0.004
p (ANOVA) - 0.156 0.130 0.011 0.002
Δ AQP2 (%)
Placebo - −19 (−29;−2) −21 (−29;−18) −21 (−28;−12) −13 (−23;−3) 0.233
Tolvaptan 15 mg - −18 (−26;−7) −13 (−18;−7) −9 (−18;−2) −4 (−18;11)
Tolvaptan 30 mg - −14 (−26;−5) −19 (−28;−11) −12 (−24;−2) −4 (−13;6)
Tolvaptan 45 mg - −9 (−22;3) −13 (−22;−2) −13–23;−4) ( −2 (−11;6)
p (GLM between) 0.094
ΔFENa (%)
Placebo - −25 (−33;−9) −33 (−40;−28) −12 (−30;1) 4 (−11;25) 0.433
Tolvaptan 15 mg - −14 (−28;−3) −17 (−23;8) 17 (−5;34) 46 (0;55)
Tolvaptan 30 mg - −15 (−18;9) −10 (−18;9) 13 (0;19) 44 (19;61)
Tolvaptan 45 mg - −12 (−28;4) −9 (−26;4) 3 (11;64) 45 (19;91)
p (GLM between) 0.014
p (ANOVA) - 0.207 0.009 0.014 0.021
Δ ENaCγ (%)
Placebo - −11 (−16;−7) −8 (−20;−3) −11 (−23;−3) 2 (−13;18)
Tolvaptan 15 mg - −9 (−21;−2) −7 (−15;22) 5 (−8;13) 6 (−7;−21)
Tolvaptan 30 mg - −3 (−13;3) −5 (−10;5) 3 (−1; 13) 8 (−8;19)
Tolvaptan 45 mg - −13 (−21;3) −5 (−10;6) −2 (−8;10) 13 (−7;18)
p (Friedman) - 0.564 0.392 0.008 0.031
Data are presented as mean ± SD or medians with 25 th and 75 th percentiles in parentheses. General linear model (GLM) with repeated measures was
performed for comparison within and between groups or Friedman test for comparison between groups. One-way ANOVA was used to test differences
between tolvaptan 15, 30 and 45 mg vs placebo. Paired t-test was used for comparison between the three tolvaptan doses at baseline period (0–90 min),
L-NMMA period (90–150 min) and post infusion period (150–210 min); the significance levels are listed under the result section
Al Therwani et al. BMC Nephrology  (2017) 18:86 Page 5 of 11
No dose response pattern was seen either in the ab-
solute or relative measurements of FENa.
U-AQP2 and U-ENaCγ
During tolvaptan with NO-inhibition 90–120 min, u-AQP2
decreased to the same level within all treatment arms. The
same response was observed in the relative changes. During
the post infusion period 180–210 min, u-AQP2 remained
reduced during placebo treatment, but had increased to
baseline level during all tolvaptan doses. No dose response
pattern was seen, in either the absolute or relative measure-
ments of u-AQP2 (Fig. 1d and Table 1).
Fig. 1 Effect of tolvaptan 15, 30 and 45 mg at baseline, during and after NO-inhibition on GFR (51 Cr-EDTA-clearance) (a), UO (b), CH2O (c) and
u-AQP2 (d). Data are presented as mean ± SEM. General linear model (GLM) with repeated measures was performed for comparison within and
between groups. One-way ANOVA (*) was used to test differences between tolvaptan 15, 30 and 45 mg vs placebo. Paired t-test (α/β/γ) was used
for comparison of infusion period (90–150 min) vs baseline period (0–90 min) and post infusion period (150–210 min) vs baseline period.† p<;
0.05; †† p < 0.001; */††† p < 0.0001. Paired t-test was used for comparison between the three tolvaptan doses at baseline period (0–90 min),
L-NMMA infusion period (90–150 min) and post infusion period (150–210 min); the significance levels are listed under the result section
Fig. 2 Effect of tolvaptan 15, 30 and 45 mg at baseline, during and after NO-inhibition on FENa (e) and u-ENaCγ (f). Data are presented as mean
± SEM. General linear model (GLM) with repeated measures was performed for comparison within and between groups. One-way ANOVA (*) was
used to test differences between tolvaptan 15, 30 and 45 mg vs placebo. Paired t-test (α/β/γ) was used for comparison of infusion period (90–150 min) vs
baseline period (0–90 min) and post infusion period (150–210 min) vs baseline period. † p<; 0.05; †† p< 0.001; */††† p< 0.0001. Paired t-test was used for
comparison between the three tolvaptan doses at baseline period (0–90 min), L-NMMA infusion period (90–150 min) and post infusion period
(150–210 min); the significance levels are listed under the result section
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During tolvaptan with NO-inhibition 90–120 min,
u-ENaCγ decreased significantly after placebo, but
during tolvaptan treatment no significant differences
existed between the placebo group and the three tol-
vaptan doses either in absolute or relative measure-
ments (Fig. 2f and Table 1). During the post infusion
period 180–210 min, u-ENaCγ was unchanged com-
pared to baseline measurement both during placebo
and tolvaptan treatment. A significant difference was
measured in the relative values with a dose response
pattern and the highest increase during the highest
tolvaptan dosis (Table 1).
Plasma sodium and plasma osmolarity
At baseline, p-Na and p-osm were significantly higher
and similar after tolvaptan 15, 30 and 45 mg compared
to placebo and this response was sustained during tol-
vaptan with NO-inhibition (Additional file 2: Table S2).
Vasoactive hormones
During tolvaptan with NO-inhibition, none of the vaso-
active hormones were affected a part from the sustained
3- fold increase in p-AVP after all three tolvaptan doses
(Additional file 3: Table S3).
Brachial blood pressure
During baseline conditions, SBP, DBP and pulse rate
were the same within all treatments (Additional file 4:
Table S4).
In response to tolvaptan with NO-inhibition, DBP in-
creased after placebo, but remained constant after tol-
vaptan 15, 30 and 45 mg. Otherwise no differences were
measured in SBP and pulse rate.
Central blood pressure
At baseline, PWV, AI, CSBP and CDBP were identical
after tolvaptan 15, 30 and 45 mg versus placebo. Dur-
ing tolvaptan with NO-inhibition, CSBP and CDBP
increased equally after all treatments (Table 2). PWV
was not affected by L-NMMA infusion after placebo
whereas a similar increase after tolvaptan 15, 30 and
45 mg was measured, but only to the same level ob-
served after placebo. Tolvaptan 15 and 30 mg did not
change AI. The value of AI was higher after tolvaptan
45 mg. However, no differences were measured be-
tween treatment groups.
Water and sodium excretion, BP and vasoactive hormones
during baseline
51Cr-EDTA-clearance was similar after placebo and tol-
vaptan (Fig. 1a).
UO was significantly lower during placebo than tol-
vaptan treatment (Fig. 1b). UO was lower after tolvaptan
15 mg compared with tolvaptan 30 mg (p = 0.005), while
no difference was measured between tolvaptan 30 and
45 mg. CH2O was significantly lower during placebo than
tolvaptan treatment. CH2O increased significantly more
after tolvaptan 30 mg compared with 15 mg (p = 0.004),
but no further increase was measured after tolvaptan
45 mg (Fig. 1c).
FENa was the same after all treatments. No significant
difference was measured between the three tolvaptan
doses (Fig. 2e).
U-AQP2 was similar after tolvaptan 15, 30 and 45 mg
or placebo (Fig. 1d). U-ENaCγ was significantly higher
after placebo than after tolvaptan treatment, and a dose-
response effect was measured with the lowest level of
u-ENaCγ during the highest tolvaptan dosis (Fig. 2f ).
Table 2 Effect of tolvaptan 15, 30 and 45 mg at baseline, during
and after NO-inhibition on pulse wave velocity (PWV), augmentation
index (AI), central diastolic and systolic blood pressure (CBDP and
CSBP) in a randomized, placebo-controlled, double-blind, crossover,
dose-response study of 15 healthy subjects
Prior to L-NMMA
infusion (at 70 min)
During L-NMMA
infusion (at 130 min)
PWV(m/s)
Placebo 5.2 ± 0.5 5.4 ± 0.5
Tolvaptan 15 mg 5.0 ± 0.5 5.4 ± 0.6**
Tolvaptan 30 mg 5.2 ± 0.6 5.5 ± 0.6 **
Tolvaptan 45 mg 5.2 ± 0.3 5.5 ± 0.4**
p (ANOVA) 0.518 0.851
AI
Placebo −0.7 ± 13.8 0.1 ± 15.1
Tolvaptan 15 mg −1.5 ± 12.5 −1.2 ± 17.3
Tolvaptan 30 mg −0.4 ± 11.8 2.5 ± 17.8
Tolvaptan 45 mg −3.3 ± 15.8 1.6 ± 12.0*
p (ANOVA) 0.968 0.961
CSBP
Placebo 97 ± 9 100 ± 8**
Tolvaptan 15 mg 97 ± 9 101 ± 10*
Tolvaptan 30 mg 96 ± 9 102 ± 9**
Tolvaptan 45 mg 96 ± 8 102 ± 6**
p (ANOVA) 0.989 0.952
CDBP
Placebo 63 ± 7 68 ± 6***
Tolvaptan 15 mg 63 ± 7 68 ± 9**
Tolvaptan 30 mg 61 ± 6 68 ± 7***
Tolvaptan 45 mg 62 ± 5 68 ± 6**
p (ANOVA) 0.936 0.998
Data are presented as mean ± SD. One-way ANOVA was performed to test
differences between treatments groups. Paired t-test (*) was used for comparison
of data during L-NMMA infusion vs prior to L-NMMA infusion
*p < 0.05; **p < 0.001; ***p < 0.0001
Al Therwani et al. BMC Nephrology  (2017) 18:86 Page 7 of 11
PRC, p-ANGII and p-Aldo were the same after tol-
vaptan 15, 30 and 45 mg compared with placebo
(Additional file 3: Table S3). A highly significant and
non-dose dependent 3-fold increase in p-AVP was
measured after all three doses of tolvaptan (Fig. 3).
No difference was measured between the three tol-
vaptan doses (p = 0.645).
Discussion
In the present dose-response study, we investigated
short-term effects of tolvaptan on renal tubular function,
vasoactive hormones and systemic hemodynamics
during basal conditions and during tolvaptan with
NO-inhibition in healthy subject. The present study is a
continuation and expansion of a previous randomized,
double-blinded, placebo-controlled crossover, single-
dose study conducted by our laboratory [12].
At baseline, tolvaptan increased renal water excretion
dose-dependently up to 30 mg, without affecting sodium
excretion. During L-NMMA infusion, tolvaptan de-
creased water excretion dose-dependently, whereas so-
dium excretion decreased independently of the dose. In
the post infusion period, water excretion remained re-
duced during all tolvaptan doses, but increased during
placebo. Tolvaptan increased sodium excretion to a
higher level.
Recent dose-response trials have shown that oral ad-
ministration of tolvaptan 30 mg led to a fast increase in
the effective concentration in plasma. This increase was
however followed by a fast decline due to tolvaptan’s
short half-life of approximately 6–8 h [34, 35]. The abso-
lute bioavailability of tolvaptan is approximately 56%
and a plasma concentration peak (300 ng/ml) is obtained
2–4 h post-dosing. Based on the pharmacological profile
of tolvaptan, we think that oral administration of tolvap-
tan at 8:00 AM (approximately 3 h prior to L-NMMA
infusion) was the optimal time. The results from our
previous study of tolvaptan 15 mg confirmed a signifi-
cant increase in OU and CH2O that was measurable
within approximately 2-3 h post-dose [12].
In the present trial, tolvaptan increased UO and CH2O
dose-dependently when tolvaptan dose was ascended
from 15 to 30 mg during baseline, but no further in-
crease was measured after tolvaptan 45 mg. This obser-
vation does not exclude that a much higher dose might
further increase renal water excretion. In addition, a lon-
ger observation time might be needed to obtain a further
increase in UO and CH2O. Several of the participants re-
ported significant and frequent diuresis after they have
left our facilities. In previous clinical studies, using much
higher tolvaptan doses ranging from 60 to 480 mg, tol-
vaptan increased CH2O in a dose-independent relation-
ship and UO in a dose-dependent relationship [35, 36].
In these studies, UO and CH2O were collected and mea-
sured over a longer observation period around 24-h and
up to 144 h post-dose.
During L-NMMA infusion, UO and CH2O declined in
all treatment arms, confirming the well-known anti-
diuretic effect by blocking the diuretic action of NO.
However, UO remained approximately 30–50% higher
after tolvaptan, and p-AVP also remained at the high
level and unchanged from baseline. The degree of de-
cline in CH2O tended to be dependent of the tolvaptan
dose, as CH2O fell less after tolvaptan 30 and 45 mg than
after 15 mg. In the post infusion period, UO and CH2O
remained reduced to the same levels during the three
tolvaptan doses. This may reflect an interaction between
the V2 receptor system and the NO system, expressed as
a higher level of water excretion after tolvaptan. Thus,
tolvaptan partly antagonized the antidiuretic action of
L-NMMA. This is in agreement with NO having a
stimulating effect on renal water excretion in the renal
principal cells that seemed to be partly AVP-dependent.
Our results are, however, not in agreement with the
findings observed in our previous clinical study of tol-
vaptan 15 mg, in which we showed that tolvaptan poten-
tiated the antidiuretic action of L-NMMA [12]. A
possible explanation of this discrepancy could be that
tolvaptan was given 2 h earlier, at 6:00 AM versus
8:00 AM in the present study. Therefore, tolvaptan
exerted its effect over a longer period before the
L-NMMA intervention.
Tolvaptan prevented fusion of cytoplasmic vesicles
containing AQP2 to the apical membrane as response to
activation of V2 receptors by AVP [1, 2]. As a result, the
activation rate of AQP2 is declined. This response is bio-
chemically reflected as a decline in the excretion of
AQP2 into the urine [28–30]. Increased u-AQP2 reflects
Fig. 3 Effect of tolvaptan 15, 30 and 45 mg on p-AVP at baseline,
during and after NO-inhibition. Data are depicted as mean ± SEM.
Friedman test was used for comparison between treatment groups
prior to L-NMMA infusion, at the end of L-NMMA infusion and 1 h
after the end of L-NMMA infusion
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increased water transport from the tubular lumen to the
intracellular space via the aquaporin2 water channels, lo-
cated in the principal cells in the distal part of the neph-
ron [28, 30]. Surprisingly, u-AQP2 did not change after
oral administration of tolvaptan, not even in response to
the highest dose of tolvaptan. We measured a similar re-
sponse in our previous study of tolvaptan 15 mg [12].
Most likely, this could be explained by the measured 3-
fold increase in plasma AVP. The increase in AVP exerts
a competitive inhibition on the V2 receptor, thereby
interfering with tolvaptan’s binding to the V2 receptor.
Alternatively, the baseline period could be too short to
reflect the expected decline in u-AQP2 after oral admin-
istration of tolvaptan.
At baseline, FENa was identical after all treatments,
whereas u-ENaCγ decreased dose-independently after
tolvaptan. Several experimental and clinical trials have
appointed the AVP-V2R-ENaCγ axis as an essential
physiological mechanism in the final regulation of so-
dium excretion [6, 37]. Our findings are in agreement
with these results, as we measured a reduced and similar
baseline level of u-ENaCγ after all tolvaptan doses. There
was a clear tendency to a dose-response pattern with the
lowest u-ENaCγ at the highest dosis of tolvaptan. How-
ever, we did not measure an increase in FENa. This ob-
servation could be explained by the primarily aquaretic
effect of selective V2R antagonism that is shown to be
approximately 4 times the natriuretic effect [6].
During tolvaptan with NO-inhibition, FENa declined
less pronouncedly after tolvaptan and the degree of the
decline was not dependent of tolvaptan dosis. The so-
dium transport via the epithelial sodium channels is sup-
posed to be reflected by the level of urinary excretion of
a protein fraction from the channels (u-ENaCγ) [29, 38].
U-ENaCγ decreased after placebo and remained un-
changed, but at a lower level after tolvaptan treatment.
In the post infusion period, FENa increased more and
dose-independently after tolvaptan. U-ENaCγ also in-
creased, but with a dose response relationship and the
highest increase was measured during tolvaptan 45 mg.
This observation was different from our previous single-
dose study of tolvaptan, where u- ENaCγ increased after
NO-inhibition and remained higher in the post infusion
period. This in turn, could also be attributed to the 2 h
longer reaction time for tolvaptan in the first study [12],
during which the effective concentration in plasma may
have been lowered owing tolvaptan’s relatively short
half-life. Therefore, a lesser effect remained when
L-NMMA was administered. Thus, tolvaptan inhibited
the antinatriuretic effect of systemic NO-inhibition par-
tially via an AVP-dependent pathway, and the degree of
inhibition followed a dose-independent relationship.
We measured a significant and three-fold non-dose-
dependent increase in p-AVP after all three tolvaptan
doses. Endogenous AVP release appeared to reach a
plateau at a tolvaptan dose of 15 mg. This compensatory
release of AVP due to treatment with V2 receptor antag-
onist is well documented [26]. However, the absence of a
dose-response pattern in vasopressin has previously been
demonstrated during tolvaptan treatment. Also, this re-
sponse in plasma AVP was not affected by inhibition of
systemic NO after all treatments. Thus, NO did not seem
to play a role in the AVP releasing mechanism. Our results
are in agreement with previous studies [6, 12].
Brachial and central BP remained unaffected even with
an approximate 3-fold increase in p-AVP after tolvaptan
15, 30 amd 45 mg. Applanation tonometry was also per-
formed under standardized conditions. The method is
described and evaluated elsewhere [39]. Inhibition of
systemic NO synthesis caused an increase in cBP, but to
the same level within all treatments. In addition to its
aquaretic effect, tolvaptan is believed to exert a pressor
effect via the V1a receptors, localized in the vascular
smooth muscle cells, as a consequence of compensatory
increased endogenous AVP release. In turn, AVP may
activate the V1a receptors at high plasma levels [6].
However, we demonstrated that an increase in tolvaptan
dose from 15 to 45 mg had no effect on bBP and cBP.
This is in good agreement with the fact that we did not
measure changes in P-AngII, PRC or P-Aldo after any
of the three tolvaptan doses. In other words, we
could not reject the null hypothesis, saying that tol-
vaptan would not change blood pressure using differ-
ent doses of tolvaptan.
During baseline conditions, we measured a non-dose
dependent increase in p-Na and p-osm after tolvaptan.
Plasma sodium and p-osm remained 141 mmol/L and
288 mosm/kg respectively, even after tolvaptan 45 mg.
Most likely, the response in p-Na and p-osm must be
due to increased renal water excretion and consequently
decline in the extracellular volume. V2 receptor antag-
onism has previously been shown to increase p-Na and
p-osm in a non-dose-response manner [12, 34, 36]. The
abovementioned parameters were not affected by NO in-
hibition. The results are in agreement with a previous
clinical study reported by our laboratory [12].
Strengths and limitations
The major strengths of our study are a combination of
the study design as randomized, placebo-controlled,
double-blinded, crossover trial, and the standardized diet
and fluid intake to avoid any confounding of the results.
It might be considered as a weakness of the study that
the assumption of abrogated systemic NO synthesis was
exclusively based on the measurement of the response in
51Cr-EDTA-clearance, CH2O, UO, u-AQP2, FENa and
mean arterial blood pressure. A measurement of nitrate
or nitrite in plasma or urine could have documented the
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NO inhibition directly, but this method is difficult, and
according to our experience not as reliable as the
methods used in the present study.
Emerging data indicate that the regulated protein frac-
tions of AQP2 and ENaCγ are excreted as urinary exo-
somes. These fraction were not isolated and analyzed in
the present study.
We cannot exclude possible gender differences in the
parameters studied due to female predominance.
Conclusions
During baseline conditions, tolvaptan increased renal water
excretion dose-dependently, whereas tubular handling of so-
dium was unchanged. During tolvaptan with NO-inhibition,
renal water excretion was reduced dose-dependently, and
renal sodium excretion non-dose-dependently partly via an
AVP-dependent mechanism. The lack of decrease in u-
AQP2 by tolvaptan could be explained by a counteracting
effect of elevated vasopressin in plasma.
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